Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. reported a revenue of 349 million yuan and a net profit of 27.8 million yuan for the first half of 2025, alongside a cash dividend plan of 8.8 million yuan to shareholders [2] Group 1: Financial Performance - The company achieved a revenue of 349 million yuan and a net profit of 27.8 million yuan during the reporting period [2] - The small molecule business generated a revenue of 248 million yuan, reflecting a year-on-year growth of 17.44% [2] - The compound annual growth rate (CAGR) of the company's revenue from 2022 to 2024 is 19.75% [2] Group 2: R&D and Technological Advancements - The company has overcome challenges in chromatography linear scaling technology, enabling product scaling from grams to kilograms [3] - R&D expenses for the first half of the year amounted to 20.99 million yuan, with a CAGR of 20.14% in R&D investment over the past three years [3] - Ongoing projects include the development of high-efficiency peptide synthesis and purification equipment, utilizing advanced industry technologies [3] Group 3: Market Outlook and Strategic Focus - The global chromatography equipment market is expanding, particularly in China, driven by the rapid development of downstream industries [3] - The company plans to continue focusing on its core chromatography product business, enhancing product performance based on market demand [3] - The goal is to become a leading enterprise in the R&D, production, and industrialization of chromatography separation and purification equipment in China [3]
小分子药物分离纯化业务稳中有进 汉邦科技上半年实现营业收入3.49亿元